New analysis method for predicting the risks and effects of immunotherapy

In a new study, researchers have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.

source https://www.sciencedaily.com/releases/2020/12/201211100617.htm